Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis

References

• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940–944.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Boubaya M, et al. EUSTAR group. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897–1905.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int. 2017;37:853–886.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–1254.
   PubMed Web of Science ®Google Scholar
• Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146:422–436.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Graf N, et al. EUSTAR Collaborators. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019;78:648–656.
   PubMed Web of Science ®Google Scholar
• Nevskaya T, Zheng B, Baxter CA, et al. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2020;59:1715–1724.
   PubMed Web of Science ®Google Scholar
• Khanna D, Furst DE, Clements PJ; Relaxin Study Group, et al. Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005;32:832–840.
   PubMed Web of Science ®Google Scholar
• Hudson M, Steele R, Taillefer S, et al. Canadian Scleroderma Research. Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 2008;59:270–278.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16:911–924.
   PubMed Web of Science ®Google Scholar
• Smith V, Scirè CA, Talarico R, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2018;4:e000782.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J; EUSTAR Coauthors, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–1339.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
   PubMed Web of Science ®Google Scholar
• Orlandi M, Barsotti S, Lepri G, et al. One year in review 2018: systemic sclerosis. Clin Exp Rheumatol. 2018;36(Suppl 113):3–23.
   PubMedGoogle Scholar
• Barsotti S, Orlandi M, Codullo V, et al. One year in review 2019: systemic sclerosis. Clin Exp Rheumatol. 2019;37(Suppl 119):3–14.
   PubMedGoogle Scholar
• Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255–273.
   PubMed Web of Science ®Google Scholar
• Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311–322.
   PubMed Web of Science ®Google Scholar
• Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis. 2010;69(Suppl1):i48–51.
   PubMedGoogle Scholar
• Bujor AM, Asano Y, Haines P, et al. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum. 2011;63:1729–1737.
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62:1733–1743.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308–1316.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60:219–224.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16.
   PubMed Web of Science ®Google Scholar
• Kumánovics G, Péntek M, Bae S, et al. Assessment of skin involvement in systemic sclerosis. Rheumatology (Oxford). 2017;56:v53–v66.
   PubMedGoogle Scholar
• Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2:11–18.
   PubMed Web of Science ®Google Scholar
• Pope J. Measures of systemic sclerosis (scleroderma): health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler’s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud’s Condition Score (RCS). Arthritis Care Res (Hoboken). 2011;63(Suppl11):S98–111.
   PubMedGoogle Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785–794.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463.
   PubMed Web of Science ®Google Scholar
• Tamaki Z, Asano Y, Hatano M, et al. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol. 2012;22:94–99.
   PubMed Web of Science ®Google Scholar
• Castelino FV, Bhattacharyya S, Varga J. Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib. Curr Rheumatol Rep. 2009;11:161–163.
   PubMedGoogle Scholar
• Sabnani I, Zucker MJ, Rosenstein ED, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009;48(1):49–52.
   PubMed Web of Science ®Google Scholar
• Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 2009;60:584–591.
   PubMed Web of Science ®Google Scholar
• van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum. 2008;58:2549–2552.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008;47:735–737.
   PubMed Web of Science ®Google Scholar
• Haddon DJ, Wand HE, Jarrell JA, et al. Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment. J Rheumatol. 2017;44:631–638.
   PubMed Web of Science ®Google Scholar
• Divekar AA, Khanna D, Abtin F, et al. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the bronchoalveolar lavage of patients with systemic sclerosis. Clin Immunol. 2011;141:293–303.
   PubMed Web of Science ®Google Scholar
• Pope J, Walker KM, de Leon F, et al. Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study. Rheumatology (Oxford). 2014;53:1830–1834.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003–1009.
   PubMed Web of Science ®Google Scholar
• Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540–3546.
   PubMed Web of Science ®Google Scholar
• Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63:3547–3551.
   PubMed Web of Science ®Google Scholar
• Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167:1138–1144.
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Gabrielli B, Pomponio G; Imatinib in Scleroderma Italian Study Group, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
   PubMed Web of Science ®Google Scholar
• Guo L, Chen XX, Gu YY, et al. Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clin Rheumatol. 2012;31:1395–1400.
   PubMed Web of Science ®Google Scholar
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–590.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
   PubMed Web of Science ®Google Scholar
• Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47(Suppl5):v2–4.
   PubMedGoogle Scholar
• Khanna D, Clements PJ, Volkmann ER, et al. Minimal clinically important differences for the modified Rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II). Arthritis Res Ther. 2019;21:23.
   PubMed Web of Science ®Google Scholar
• van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:3643–3672.
   Google Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–1358.
   PubMed Web of Science ®Google Scholar
• Namas R, Tashkin DP, Furst DE, et al. Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken). 2018;70:439–444.
   PubMed Web of Science ®Google Scholar
• Poormoghim H, Rezaei N, Sheidaie Z, et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int. 2014;34:1691–1699.
   PubMed Web of Science ®Google Scholar
• Shouval R, Furie N, Raanani P, et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018;24:937–944.
   PubMedGoogle Scholar
• van Laar JM, Farge D, Sont JK; EBMT/EULAR Scleroderma Study Group, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498–506.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Onida F, Zaccara E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant. 2017;52:53–58.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M; SENSCIS Trial Investigators, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–2528.
   PubMed Web of Science ®Google Scholar
• Amjadi S, Maranian P, Furst DE, et al. Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009;60:2490–2498.
   PubMed Web of Science ®Google Scholar
• Khanna D, Berrocal VJ, Giannini EH, et al. The American college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2016;68:299–311.
   PubMed Web of Science ®Google Scholar
• Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3:e2696.
   PubMed Web of Science ®Google Scholar
• Hinchcliff M, Huang CC, Ishida W, et al. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol. 2012;30:S86–96.
   PubMed Web of Science ®Google Scholar
• Sargent JL, Whitfield ML. Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol. 2011;7:463–473.
   PubMed Web of Science ®Google Scholar
• López-Isac E, Acosta-Herrera M, Kerick M, et al. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis (GENESYF). Nat Commun. 2019;10:4955.
   PubMed Web of Science ®Google Scholar